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CONTINUING MEDICAL EDUCATION
Screening, early detection, and trends for melanoma:
Current status (2000-2006) and future directions
Alan C. Geller, MPH, RN,a,b Susan M. Swetter, MD,c Katie Brooks, MPH,a
Marie-France Demierre, MD,a and Amy L. Yaroch, PhDd
Boston, Massachusetts; Palo Alto, California; and Bethesda, Maryland
In the past 5 years, there have been notable strides toward the earlier recognition and discovery of
melanoma, including new technologies to complement and augment the clinical examination and new
insights to help clinicians recognize early melanoma. However, incidence and mortality rates throughout
most of the developed world have risen over the past 25 years, while education and screening, potentially
the best means for reducing the disease, continue to be severely underutilized. Much progress needs to be
made to reach middle-aged and older men and persons of lower socioeconomic status who suffer a
disproportionate burden of death from melanoma. Worldwide melanoma control must also be a priority,
and comprehensive educational and screening programs should be directed to Northern Ireland and a
number of Eastern European nations, whose 5-year survival rates range between 53% and 60%, mirroring
those of the United States and Australia more than 40 years ago.
Learning objective: After completing this learning activity, participants should be aware of the most
recent melanoma epidemiologic data, both in the United States and internationally; worldwide early
detection and screening programs; clinical strategies to recognize and improve the detection of early
melanoma; the latest technologies for early detection of melanoma; and public and professional education
programs designed to enhance early detection. ( J Am Acad Dermatol 2007;57:555-72.)
M
elanoma is an increasingly common can-
cer in the United States and elsewhere.
Screening and early detection programs
can ideally detect nearly all melanoma at a curable
and early stage. In this review,we highlight emerging
national and international incidence and mortality
trends, advances in clinical strategies for the detec-
tion of early melanoma, worldwide screening and
educational programs, new technologies for early
identification of lesions, and public and professional
education to promote early detection of disease.
We reviewed MEDLINE and national and inter-
national registries and databases using search terms
such as melanoma, incidence, mortality, early de-
tection, screening, physical exam, sensitivity,
specificity, screening, self-screening, identification,
recognition, and dermoscopy/dermatoscopy. We
identified additional studies by reviewing the refer-
ence lists of all studies included herein and consulted
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ACS: American Cancer Society
BSCT: Basic Skin Cancer Triage
CAMS: classic atypical mole syndrome
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CI: confidence interval
DN: dysplastic nevi
FDR: first-degree relatives
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with experts to ensure that all relevant studies were
covered. Every effort was made to use only the most
recently published studies (2000-2006); in some
cases, key studies before 2000 were included.
INCIDENCE AND MORTALITY TRENDS
IN THE UNITED STATES AND
INTERNATIONALLY
The American Cancer Society (ACS) estimates that
there will be 59,940 cases of melanoma in the United
States in 2007 (33,910 cases in males, and 26,030
cases in females). Estimates also indicate that there
will be 8110 melanoma deaths (5220 in males; 2890
females).1
Incidence trends
Both in the United States and throughout most of
the world, the incidence of melanoma has been
increasing steadily over the past few decades. In fact,
in the United States, the overall age-adjusted inci-
dence among non-Hispanic whites has increased
from 7.5 cases per 100,000 in 1973 to 21.9 cases per
100,000 in 2002, an increase of nearly 200%, with
disproportionate increases in persons over the age of
55 years.2 Two-thirds of all melanomas diagnosed in
the United States between 1988 and 1999 were
\1 mm, while the proportion of $ 2 mm lesions
(14.4% to 15.5%) has remained the same.3
Incidence rates between 1973 and 2002 have risen
in all age groups and in both men and women;
however, men between the ages of 55 and 64 years
have experienced more than a 4-fold increase (12.4
to 56.1 per 100,000), and rates have risen more than
5-fold in men aged 65 years and older (18.8 to 104.4
per 100,000; Fig 1). One study contended that the
higher numbers of biopsies among the Medicare
population in recent years are the cause for these
rates, rather than true increases in incidence.4 Recent
data from New South Wales (Australia)5 indicates
stabilizing incidence rates in younger men and
declining rates in younger women. In this data,
only men aged 75 years and older show increasing
incidence rates (7.2% per year). In Sweden, the
overall incidence rates remained stable for 1990
through 1999, with declining rates in younger and
female patients offset by lack of progress for older
patients, men, and individuals with truncal lesions
and nodular melanoma.6
In the United States, the incidence of melanoma
among African Americans and Hispanics is dramat-
ically lower than that among whites; however, rates
are slowly increasing in these groups as well. From
1992 to 2002, incidence among black males in-
creased from 0.58 to 1.00, and in black females
increased from 0.58 to 0.95. Among Hispanic males,
incidence increased from 3.11 in 1992 to 4.68 in 2002.
Melanoma incidence among Hispanic women in-
creased from 3.38 to 4.05 during this same period.2
In Scotland (1979-1998), the incidence rate rose
more sharply in men than women, reversing earlier
trends, and occurred in melanomas of all thicknesses
in men. In women, only melanomas thinner than
Fig 1. Melanoma incidence among non-Hispanic whites, 1973 and 2002, by age and gender.
(Data taken from the Surveillance, Epidemiology, and End Results [SEER] Program SEER*Stat
Database. Incidence - SEER 9 Regs Public Use [1973-2002], National Cancer Institute, DCCPS,
Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the
November 2004 submission. Available from www.seer.cancer.gov).
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1.5 mm increased in incidence. The most frequent
body sites for melanoma include the trunk, head,
and neck in men and the legs in females.7
De Vries et al8,9 analyzed 211,557 incident cases of
melanoma recorded during from 1953 to 1998 from
63 European cancer registries. Incidence rates vary
significantly depending on the geographic location,
with higher rates in northern European countries
(such as Norway and Sweden) and lower rates in
southern and eastern Europe (such as Poland and
Italy). It has been hypothesized that this latitudinal
gradient may be related to sun exposure behaviors,
and in particular to the tendency for Northern
Europeans to vacation in sunny climates, resulting
in intense, intermittent sun exposure. Encouragingly,
the rate of increase has begun to subside, and in some
cases has actually decreased in younger age groups in
northern Europe (ie, Denmark, Norway, and Swe-
den). However, incidence rates continue to rise in
older men and women. In addition, in most of the
western, eastern, and southern European countries
(ie, France, Slovakia, and Slovenia) melanoma inci-
dence continues to increase.
Mortality
In 1973, the mortality rate among non-Hispanic
whites in the United States was 2.1 per 100,000; in
2002, this number increased to 2.9 per 100,000.2
Since 1992, however, there has been no change in
mortality among men and a reduction in mortality
among women.
With regard to specific age groups, between 1973
and 2002, melanoma mortality decreased by 23% in
women aged 20 to 54 years and by 11% in men in
the same age range. In contrast, mortality rates rose
15% in women aged 55 to 64 years and 64% in men
of the same age range. Mortality rates increased
130% (8.6 to 19.8 per 100,000) in men aged 65 years
or older, and 73% in women of the same age group
(Fig 2).2
American stateswith thehighest rates of death from
melanoma are New Hampshire, Oklahoma, Maine,
Utah, and Idaho (Table I).2 Specific information on
factors that may be associated with state-by-state rates
of mortality, such as incidence, dermatology care,
social class, rural versus urban residence, and surgical
care, are unavailable. Therefore, new attention
should be given to developing such databases. It is
worth noting that nearly all of the 10 states with
highestmelanomamortality are in the bottom third of
US population ranking, and only one is among the
most populous 25 states.
Worldwide, mortality rates are highest in New
Zealand, Australia, Norway, Denmark, and South
Africa (Table II), among others.10-16 Mortality rates
are uniformly higher in males than females. Rates are
rising worldwide, most precipitously in older men,
with women of the same age experiencing smaller
increases. Mortality rates are decreasing or stabilizing
for younger women, and rates among younger men
vary by country. For example, mortality has leveled
off in Sweden since the mid-1980s, and in particular
Fig 2. Melanoma mortality among non-Hispanic whites, 1973 and 2002, by age and gender.
(Data taken from the Surveillance, Epidemiology, and End Results [SEER] Program SEER*Stat
Database. Mortality - All COD, Public-Use with State, Total U.S. [1969-2002], National Cancer
Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005.
Underlying mortality data provided by NCHS [www.cdc.gov/nchs].)
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a statistically significant downward trend was ob-
served in females.16
Survival
Remarkably, 5-year survival rates now exceed
90% in certain countries, including the United States,
Australia, and Sweden. The overall 5-year relative
survival rate between 1995 and 2001 from nine US
Surveillance, Epidemiology, and End Results (SEER)
geographic areas was 91.6% (90.3% for white men;
93.5% for white women).2 In Scotland, survival rates
that were as low as 58% in men in 1978 jumped
to 80% in 1993 (P \ .001).7 Case-fatality rates, an
important indicator for survival, have improved
dramatically in South Australia in only 20 years,
and the case-fatality rate for the 1994 to 2000 diag-
nostic period was 0.79 (95% CI 0.63-0.99) when
compared with the 1980 to 1986 baseline.17
However, it appears that many nations have not
benefitted from early detection and educational
programs. Low rates of 5-year survival have been
found amongmen inNorthern Ireland (53.5), Cracow
(55.8), the Czech Republic (60.3), and Slovenia
(60.6), equaling survival rates in the United States
and Australia from more than 40 years ago. Survival
rates for women generally fared no better in these
four countries, and women had surprisingly high
rates of truncal melanoma.10
Economics serves as another measure of the
human toll of melanoma. In the United States, the
annual direct cost of treating newly diagnosed mel-
anoma in 1997 was estimated to be $563 million.
Stage I and II disease each comprised about 5% of the
total cost; stage III and IV disease consumed 34% and
55% of the total cost, respectively. About 90% of the
total annual direct cost of treating melanoma in 1997
was attributable to\20% of patients, primarily those
with stage III and IV disease.18
Summary
Incidence and mortality rates rose precipitously
throughout most of the developed and industrialized
world from the 1960s through the 1990s.While it may
take decades for the effect of primary prevention on
melanoma incidence to become evident, public
health efforts to promote sun protection and tanning
bed avoidance must be vigilantly implemented and
maintained. Early detection efforts (secondary pre-
vention) may result in reductions in mortality more
quickly than sun protection campaigns, and inter-
ventions will bemost successful if they target those at
greatest risk of disease (see the section on early
detection below). Web sites for exploring national
and international incidence and mortality trends
include Globo Can (http://www-dep.iarc.fr/globocan/
downloads.html) and SEER (http://seer.cancer.gov/).
CLINICAL STRATEGIES FOR EARLIER
RECOGNITION AND IDENTIFICATION
Recent advances have heightened our under-
standing of recognition patterns, the descriptive
epidemiology of ‘‘melanoma histogenetic type
Table I. States with top ten highest rates of
mortality related to melanoma (all races)*
State
Annual death
rate
Dermatologist/
capita rank
Population
rank
New Hampshire 3.9 (2.9, 5.2) 22 41
Oklahoma 3.5 (2.9, 4.1) 45 27
Maine 3.5 (2.6, 4.6) 47 40
Utah 3.4 (2.6, 4.4) 16 34
Idaho 3.4 (2.4, 4.6) 29 39
Oregon 3.3 (2.7, 3.9) 10 28
Vermont 3.3 (2.1, 5.1) 30 49
Wyoming 3.2 (1.8, 5.3) 48 51
Kentucky 3.1 (2.6, 3.7) 27 25
Nebraska 3.1 (2.3, 4.0) 38 38
Death data provided by the National Vital Statistics System public
use data file. Death rates calculated by the National Cancer
Institute using SEER*Stat. Death rates are age-adjusted to the 2000
United States standard population by 5-year age groups.
Population counts for denominators are based on Census
populations as modified by the National Cancer Institute.
(Available from: http://statecancerprofiles.cancer.gov)
The number of dermatologists per state was taken from personal
correspondence with Barbara Paez, the Member Services
Coordinator of the American Academy of Dermatology, on
December 6, 2005.
Population data were taken from the 2000 United States Census
(www.census.gov).
*States are shown with their ranking of number of dermatologists
per capita in the state (including Washington, DC; 1 = the most
dermatologists/capita, 51 = the fewest dermatologists/capita) and
with their population size rank (1 = most populous, 51 = least
populous).
Table II. Mortality rates for melanoma 2002: Top
ten in the world (among those with at least 100
deaths)
Country
Adjusted mortality
rate, males
Adjusted mortality
rate, females
New Zealand 6.1 3.6
Australia 5.1 2.6
Norway 3.8 2.1
Denmark 3.3 2.2
South Africa 3.1 2.4
Sweden 2.9 1.6
Switzerland 2.7 1.6
Kazakhstan 2.7 2.0
Czech Republic 2.6 1.6
United States 2.6 1.3
Data from Ferlay J et al15 (available from: http://www-dep.iarc.fr/
globocan/downloads.htm).
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epidemiology,’’ the relationship between moles and
melanoma, and risk factors for melanoma.
Recognition patterns
Abbasi et al19 conducted a Cochrane Library and
PubMed search to re-evaluate the so-called ABCD
and to assess literature on evolving lesions. Current
data did not support the revision in small diameter
lesions, but the review led to a new recommendation
for the addition of E for ‘‘evolving’’ to the current
ABCD mnemonic.20
Many melanomas do not commonly meet the
ABCD criteria. For example, early melanoma is
frequently \5 mm in diameter, and nodular and
desmoplastic melanomas do not commonly meet
the A, B, and C criteria. Conversely, many seborrheic
keratoses and atypical nevi fulfill most of the ABCD
criteria. Testing the practical utility of the ABCD rule
in physician practice, Gachon et al21 investigated the
practice of 135 volunteer dermatologists and re-
corded the immediate perceptions and intuitive
diagnostic opinion about 4036 consecutive nevi
and melanoma. They found that dermatologists
generally rely more on the overall pattern and
‘‘ugly duckling sign’’22 rather than more well-known
algorithms such as the ABCD rule. In a multivariate
model attempting to predict what ‘‘clues’’ a physician
uses for diagnosing melanoma, overall irregularity,
the ugly duckling sign, and recent change according
to the patient stood out. Further studies are required
to see if this recognition process can be used for
teaching to the lay public or non-dermatologist
physician. Likewise, in dermoscopy (see dermo-
scopy section), overall pattern recognition has
been shown to be more accurate than specific
ABCD criteria.23
Melanoma histogenetic type epidemiology
During the last few decades, the incidence of thick
melanoma has remained stable in most of Australia,
the United States, and Western Europe, with little
progress in detecting ‘‘early’’ nodular melanoma.
In an analysis of more than 35,000 invasive mel-
anomas from the US SEER Registry (1988-1999),
nodular melanoma comprised only 9% of all lesions
but accounted for nearly 50% of melanomas 2 mm or
deeper when melanomas not otherwise specified
were excluded. Median thickness of nodular mela-
noma changed little from 1988 to 1991 (2.14 mm) to
1995 to 1999 (2.16 mm), and nodular melanoma
were nearly 4 times thicker than superficial spread-
ing melanoma (SSM; 0.54 mm, median thickness).3
The world’s only outlier appears to be in the South
Australia population-based registry, where the pro-
portion of nodular melanoma/all invasive melanoma
dropped from 18.5% (1980-1986) to 10.7% (1994-
2000).17 In Italy, nodular melanoma also comprised a
higher percentage of $ 2 mm lesions than SSM (65%
vs 10%).24 More than 60% of melanomas $ 3.5 mm
accessioned by the Scottish Melanoma Group were
nodular disease, with a trend toward older cases in
more recent years ([65% of the thickest cases were
in individuals $ 65 years of age).25
Because thick melanoma is often nodular disease,
there is a strong interest in the clinical presentation
and biologic factors of this tumor subtype. Few
studies have examined differences between ear-
ly/late nodular melanoma (NM) or nodular/SSM of
similar thickness. Among 54 patients in Sweden, NM
patients generally reported that their melanoma was
a new lesion, while patients with SSM generally
reported a previous pigmented lesion at the site of
the melanoma. Thin NM appeared to be smaller in
diameter than thick NM.26 Telltale signs of early SSMs
do not appear to be uniformly present in NM. NMs
were found more often than SSMs to be symmetric
(80%), elevated, uniform in color, and nonpig-
mented (50% were amelanotic [red or pink]), strik-
ingly different from SSMs, which were primarily
brown or black.27 Color change among NM was
uncommon. Patients with NM were 10 years older,
and their tumors were nearly 3 mm thicker. Liu et al28
found that male sex, older age, and fewer melano-
cytic nevi were associated with rapid tumor growth.
Rapidly growing melanomas were frequently sym-
metric, amelanotic, elevated, had regular borders,
and were symptomatic.28
In a recent population-based study in Queens-
land, for nearly allmelanoma cases, the time between
recognition of an abnormality and diagnosis of mel-
anoma apparently does not influence the thickness
of the lesion, with the exception of NM, for which
there was a positive association with melanoma
thickness. The thickness of these lesions was nearly
3% greater per month for each extra month between
initial physician identification and diagnosis.29 Like-
wise, Liu et al28 recently reported that nodular mel-
anoma grows at 4 times the rate of either SSM or
lentigo maligna melanoma (LMM), with an increase
of nearly half a millimeter per month.
There are important lessons for melanoma dis-
covery. NMswere self-detectedmore frequently than
SSMs, leading authors to speculate that quickly
growing tumors are more likely to draw the attention
of the patient, while slow-growing types are more
likely to go unnoticed.29 Unfortunately, the reduced
‘‘patient delay’’ in this instance is not associated with
thin NM. Moreover, the shorter period of evolution
of NM appears to limit the opportunity for detection
by physicians. Demierre30 commented that the
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association of NMs with solar/actinic keratosis re-
ported by Chamberlain et al and other investigators
suggested distinct pathways of melanoma suscepti-
bility. Indeed, a proposed dual pathway hypothesis
supported by recent genetic data provides a foun-
dation to develop a risk prediction tool for
melanoma.31
Invasive LMM has also increased in individuals
aged 65 and older, and in a study of the Northern
California SEER site, LMM comprises 27% of all inva-
sive melanoma in men 65 years and older. Swetter
et al32 concluded that health care providers should
be particularly vigilant about screening chronically
sun-exposed skin in older, fair-complexioned males.
Amelanotic melanoma in itself is often associated
with a delay in diagnosis because of a lack of visible
pigment and clinical features which may simulate
nonmelanoma skin cancer or benign processes, such
as dermatofibroma, verruca vulgaris, or pyogenic
granuloma. While amelanotic/hypomelanotic mela-
noma accounts for an estimated 2% to 8% of all
melanomas,33,34 it frequently defies early clinical
detection, fails to meet the ABCD criteria, and poses
a challenge for dermoscopic evaluation, which uti-
lizes color and pigmented structures to differentiate
pigmented skin lesions from nonmelanocytic
neoplasms.35
The influence of age on the association
between moles and melanoma
Three recent studies have found similar associa-
tions between age and the detection of moles and
melanoma. In an analysis of the American Academy
of Dermatology (AAD) national screening programs
(n = 363 confirmed melanomas), the overall yield of
melanoma (the number of confirmed diagnoses per
number of screenees) was 1.5 per 1000 screenings,
compared with a yield of 2.6 per 1000 screenings
among men aged $ 50 years. More than 4 melano-
mas per 1000 screenees were found in men aged
$ 50 years who reported a changing mole.36
Using baseline total body photography and der-
moscopy, Banky et al37 followed 309 patients with at
least one of the following risk factors for melanoma:
personal history of melanoma, family history of
melanoma, more than 100 nevi, or more than 4
atypical nevi. In a follow-up of patients (an average
of 3 visits spanning 34 months), younger patients
(aged \50) developed new moles more so than
older patients (aged [50), but were less likely to
develop melanoma. The predictive value for a new
mole being a melanoma was greater in patients[50
years of age. Among 311 changing nevi, size was by
far the most common type of change (67%).
Changing nevi were slightly more common than
new nevi (n = 262) and far more common than
regressed nevi (n = 86). Eighteen melanomas were
detected in 309 patients; of these, 14 were in patients
with changing lesions and 4 were in patients with
new lesions. Notably, in patients\50 years of age,
\1% of all new lesions were melanomas, whereas in
patients[50 years of age, 30% were melanoma.37
While the estimated annual rate of transformation
of any single mole into melanoma was very low
(about 1 per 200,000), the lifetime risk of a mole on a
20-year-old male transforming into melanoma by
age 80 was 1 per 3164, compared with 1 per 10,800
for women. Cutaneous melanomas were associated
with precursors at least 50% of the time for patients
\30 years of age. In contrast, for patients over the
age of 60, the prevalence of melanoma being asso-
ciated with a precursor nevus was only 20%.38
Risk factors
Whiteman and Green39 developed hypothetical
tables for absolute risks for melanoma among white
patients, combining information on environmental,
phenotypic, andgenotypic causal factors. The10-year
risk of cutaneous melanoma appeared to be highest
for older persons residing in southern Australia and
the southern United States with $ 21 nevi on their
arms.39
Cho et al40 examined risk factors for melanoma in
3 large cohorts of men and women in the United
States. Among the nearly 180,000 subjects free of
cancer followed for up to 14 years, 535 histologically-
proven melanomas were included. Males had a
higher risk for head or neck and trunk lesions.
Individuals with[10 sunburns had nearly a 7-fold
higher risk of upper extremity melanoma compared
with those with no burns. The number of moles was
most strongly related to melanoma of the trunk; the
relative risk of melanoma for subjects having [10
moles was 4.67 compared with having no moles.40
Overall, the association between melanoma and
gender, number of nevi, and history of sunburn
differed significantly by anatomic site, lending sup-
port to the divergent pathway hypothesis of mela-
noma.31 Siskind et al41 sought to determine whether
melanomas arising in the head and neck that are not
LMM had different phenotypic and environmental
associations than those on other sites. Participants
with melanomas of the head and neck were signif-
icantly older than patients with melanomas of the
trunk, and patients with head and neck melanoma
also had fewer nevi.
To explore variables associated with either thin,
intermediate, or thick melanoma, Negin et al42 pro-
spectively evaluated 369 patients regarding their
signs and symptoms at the time of their initial visit.
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Gender, age, and primary site were not significantly
associated with an increasing category of Breslow
depth. In a multivariate analysis, the signs and
symptoms most strongly associated with an in-
creased category of Breslow depth were bleeding
(odds ratio [OR], 7.5), followed by pain (OR, 3.3),
lump (OR, 2.2), itching (OR, 1.9), and change in size
(OR, 1.7). Change in color and skin breakdownwere
not independently associated with an increasing
category of Breslow depth. In a recent large, popu-
lation-based Queensland study of 3772 melanomas,
the most commonly reported signs and symptoms in
patient-detected cases were changes in color, size,
and shape, or irritation or itch at themelanoma site.43
In fact, persistent lesional itching has been suggested
as perhaps the earliest symptom of melanoma in a
small percentage of cases.44
EARLY IDENTIFICATION, SCREENING,
AND EARLY DETECTION
The early identification of melanoma can be
potentially enhanced in multiple venues, such as
community-wide screenings, dermatology-led mass
screenings, non-dermatologist physician or health-
care professional surveillance, by skin-self examina-
tion (SSE), specialized pigmented lesion clinics, and
education targeted to patients and the public at
greatest risk of disease.45
Community-wide and mass screening
Because of a relatively low prevalence of mortal-
ity and the high costs for mounting such a study, no
community-based randomized trial has provided
definitive information to determine whether screen-
ing asymptomatic persons with whole-body exams
by physicians reduces mortality from skin cancer.
With the absence of any national or international
randomized screening trial, there was insufficient
evidence for an expert group such as the US Institute
of Medicine (IOM) to provide screening recommen-
dations for melanoma.46
Researchers in Australia (where such a study is
more feasible because of higher rates of melanoma)
planned and began to implement a randomized trial
of population screening.47-50 While the plan called
for eventually randomizing 44 Queensland commu-
nities, 18 were initially randomized to intervention
(n = 9) and control (n = 9) towns. The trial’s three
components included: (1) a community education
component, which aimed to provide accurate infor-
mation about melanoma and screening to residents;
(2) an education and support component for medical
practitioners, which aimed to increase awareness
of the program and to improve doctors’ skills in
screening for and diagnosing melanoma; and (3)
the provision of free skin screening services.48-50
Uptake of the whole-body skin cancer examination
was measured by surveys of residents in intervention
and control towns. Baseline rates were similar in
intervention and control towns (11.2% and 11.3%);
however, rates jumped 2 years later to 34.8% in
intervention towns compared to 13.9% in control
communities.49 Screenings were typically performed
by general practitioners (GPs) and special screening
services. More than 16,000 whole-body examina-
tions in 18 communities had been conducted, with
the following confirmed diagnoses: 33 melanomas,
259 basal cell carcinomas, and 97 squamous cell
carcinomas, with the probability of detecting any
type of skin cancer of 2.4%.50 The overall specificity
of the skin examination for melanoma was 86.1%.
Unfortunately, the study was not expanded to the 44
communities and was recently disbanded because of
a lack of governmental funding.
Dermatology-led mass screening programs
Mass, population-wide screening programs are
now commonplace in many countries, including
Australia, Belgium, Denmark, Italy, the Netherlands,
Sweden, Switzerland, the United States, and the
United Kingdom.51-58 Programs are uniformly pro-
moted by local media in advance of a screening day,
week, ormonth. Evaluations have generally centered
on the results of the screening event, and only in
Belgium has the widespread effect on the broader
community been reported.55
Analysis of the AAD National Skin Cancer
Screening Programs (1986-2001) noted that 65% of
screenees had at least one risk factor for melanoma,
and 33% reported a changing mole. Among all
screenees, nearly 80% did not have a regular derma-
tologist, 78% reported no previous AAD skin cancer
screening, 60% had never had their skin checked by
any doctor, and 51% reported that they would not
have seen a doctor for skin cancer without the free
screening. AAD national screening and educational
programs have expanded to all 50 states and pro-
vided educational messages about sun protection
and early detection to millions.52 Among nearly
250,000 screenees, 363 melanomas were diagnosed;
98% were stage I melanomas.
Sixty-five percent of Belgian dermatologists par-
ticipated in a nationwide ‘‘Melanoma Monday’’ cam-
paign. Twenty-five melanomas were confirmed in
2767 screenees.55 Follow-up analysis of the national
media campaign led to detection of 141 new mela-
nomas, more than doubling the typical monthly rate
of new cases.55 Screening programs in Padova, Italy
also found high yield (13 melanomas per 2050
screenees) and generally thin melanoma (92%
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\1.50 mm).53 Three melanomas were detected
among more than 1000 screenees in four Italian
open access clinic sessions.51
Few programs have used prescreening publicity
to reach high-risk persons who have minimal der-
matologic care. Swetter et al59 found higher rates of
confirmed skin cancer when targeting screening to
elderly white men with minimal to no previous
dermatologic care, and television, radio messages,
and personal history of skin cancer were found to be
motivating factors for older men in Utah.60
From a survey conducted within the first phase
of the Queensland randomized screening trial, fac-
tors such as history of a clinical skin examination,
concern about skin cancer, personal history of
skin cancer, and high susceptibility toward skin
cancer were important determinants of screening
intention.61
In a cost-effectiveness model, Losina et al62 found
that one-time melanoma screening of the general
population was cost-effective compared to other
cancer screening programs in the United States.
Every 2-year screening in siblings of melanoma
patients was also cost-effective. In the general pop-
ulation, one-time, every 2-year, and annual screen-
ing saved 2.5, 8.8, and 10.2 quality-adjusted life years
(QALYs) per 1000 people screened, with incremental
cost-effectiveness ratios of $7300/QALY, $58,000/
QALY, and $450,500/QALY. In siblings of melanoma
patients (relative risk [RR] = 2.24 compared to the
general population), one-time, every 2-year, and
annual screening saved 5.7, 19.2, and 22.6 QALYs
per 1000 people screened, with incremental cost-
effectiveness ratios of $3400/QALY, $24,500/QALY,
and $196,500/QALY, respectively.62
Specialized pigmented lesion clinics
Mackie et al63 popularized the use of specialized
pigmented lesion clinics (PLCs) in Scotland to pro-
vide expert and timely referral services for local
physicians and patients. Delay in patient diagnosis
was reduced in 2001; 67% of patients visited their
physician within 3 months of seeing a worrisome
pigmented lesion, compared with only 16% in
1986.63 To date, only one study has compared the
diagnostic performance of a PLC with cancer registry
data. Among 1741 PLC patients seen in a clinic in
Italy, 15 melanomas were later recorded in the local
registry. Excisions had been performed for all but
two of the cases: a missed in situ lesion and a 0.60-
mm melanoma. The PLC exam had a sensitivity of
87% and a specificity of 95%, with a rate of 5.1:1 for
excision of benign lesions that were considered
melanoma.64
Skin self-examinations
Because lesions on the skin are often visible, the
patient should notice suspicious changes. In addi-
tion, patients have the most opportunities to exam-
ine their skin.65 Although physicians detect thinner
lesions than patients, it is the patient who most often
discovers the melanotic lesion, accounting for about
half of all melanomas.66
Only one study has tested mortality reduction
associated with skin self-examinations (SSEs). Ber-
wick et al67 conducted a case-control study and
found that SSE could potentially reduce mortality
related to melanoma by 63%. More recently, SSE was
found to be a key predictor for melanoma\1 mm in
thickness.68
Only a minority of individuals actually practice
regular SSEs. In a study conducted among residents
30 years and older in Queensland, only 26% reported
performing a full-body SSE in the past 12 months.69
Among high-risk patients attending a cancer clinic,
27% reported practicing at least one SSE in the past 4
months.70 Carli68 found SSE rates of 21% (at least
once every 3 months) among more than 800 mela-
noma patients in Italy.
SSE rates also differ depending on how one
defines the skin self-exam. In a random-digit-dial
survey of adults in Rhode Island, 58% reported
examining their skin. However, when further probed
on how often and what parts of the body were
examined, only 9% were considered to thoroughly
examine their skin.71 Further describing barriers for
SSE, Weinstock et al71 found that 29% stated that they
do not think about it, 22% believed that they had no
reason to, and 15% said that there was nothing there
before. Arnold et al72 found even stronger barriers
among a sample of Boston area young adults in
whom more than half did not know what to look for
or never thought about performing a SSE.72 In a later
survey of 2126 Rhode Island and Massachusetts
adults, Weinstock et al73 found that 19% of men
and 17% of women performed a comprehensive SSE.
Having a partner and using a wall mirror were key
predictors for SSE performance. Notably, respon-
dents with less than a high school degree were less
than one-third as likely as college-educated respon-
dents to pay close attention to their skin, look at a
particular mole, do casual exams, or perform thor-
ough exams.
Other studies have examined barriers and pro-
moters for performance of SSE. A survey of 549
Connecticut residents found that family history of
cancer and past physician examination predicted SSE
in men, and that previous benign biopsy or an
abnormal mole were individual predictors for both
men and women.74 In a multivariate model designed
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to identify predictors of SSE performance, Robinson
et al75 found modifiable predictors to be attitudes,
knowledge, and confidence in performance. These
combined with nonmodifiable variables, such as
having dermatology visits with skin biopsies, at least
one NM skin cancer nonmelanoma skin cancer
(NMSC) in the past 3 years, and younger age to
account for 61% of the variability in SSE perfor-
mance.75 Of note, patients with[1 atypical nevus
(compared with none) were less likely to detect their
melanoma and this held constant after adjustment
for all other variables. Carli et al76 speculated that
patients with many moles may find it difficult to spot
suspicious lesions amidst other atypical lesions.
Few studies have sought to test the patient’s
accuracy in performing a SSE. In a study of high-
risk patients (many moles, personal or family history
of melanoma, and/or multiple dysplastic nevi) who
had practiced SSE regularly for at least a year, Muhn
et al77 tested whether an artificial increase in size of a
mole on the back could be detected by participants
conducting SSEs. This controlled trial had 3 phases;
first, one mole was changed by 2 mm, then one was
changed by 4 mm, and finally there was no change.
The sensitivities for self-detecting increases of 2 mm
and 4 mm were 58% and 75%; however, the speci-
ficity (likelihood of detecting no change when no
change occurred) was 62%.77
At least three studies have attempted to boost
performance of the SSE. Weinstock et al78 usedmole-
mapping imaging, and nearly all participants were
satisfied with the training to assist in SSE; almost half
began to perform SSE for the first time after use of the
program. After receiving images, spouses and friends
were also more frequently participating in skin
examinations.78 Phelan et al79 led a study of patient
responses to the use of photo books to augment SSE
performance. Patients with skin cancer used them
most frequently, followed by patients with many
moles. In addition, 34% of patients requested a CD in
addition to their photo book.79 A randomized trial
provided the first evidence of efficacy for involving
partners (compared with solo learning) of skills
training for the SSE.80
Physician offices
Full-body examinations by either dermatologists
or nondermatologist physicians have both shown
the potential to save lives that otherwise would have
been lost to melanoma. Of the five major ‘‘early
detectable’’ cancers (melanoma, breast, colorectal,
prostate, and cervical), only skin cancer requires an
initial visual, nontechnological skill. Dermatologist
examination of the skin has been shown to have
relatively high sensitivity and specificity. Carli et al68
recommended that dermatologists perform a total
body skin examination to identify suspect lesions,
particularly during consultations for other reasons.
However, Fisher et al81 suggested that the absence of
a standard protocol for skin exams made screening a
difficult goal to achieve in all dermatology practices.
A survey of US dermatologists82 finds that only 30%
routinely perform a total skin examination on all of
their patients.
Few studies have compared differences in tumor
thickness between physicians (either dermatologists
or nondermatologist physicians) versus self or family
detection. A multivariate analysis led by the Italian
Multidisciplinary Group on Melanoma found mela-
nomadetection by adermatologist to be the strongest
predictor of melanoma \1 mm (OR, 0.45; 95%
confidence interval [CI], 0.28-0.73).68 Likewise, a
study of Connecticut patients found that initial mel-
anomas discovered by dermatologists were more
likely to be detected below 0.75mm than those found
by nondermatologist physicians.81 Earlier recogni-
tion of melanoma by dermatologists may be partly
explained by a recent study comparing dermatologist
and primary care physician assessment of lesions.
Photographs of randomly chosen lesions were used
to evaluate the accuracy of melanoma diagnosis and
management of pigmented lesions between 101
dermatologists and 115 primary care physicians.
Dermatologists outscored primary care physicians in
both domains; however, primary care physicianswho
routinely biopsied lesions outscored counterparts
who did not tend to do so.83
Physicians also detect melanoma at earlier
stages compared to patients, spouses or family
friends.44,66,84 Epstein et al84 found differences of
nearly 0.7 mm, and Schwartz et al44 found physician-
detected melanoma (0.40 mm) to be significantly
thinner than patient (1.17 mm) or spouse-detected
melanoma (1.00 mm).
Because dermatologists have specialized training,
their practice setting is the ideal place for screening;
however, most Americans will never see a dermatol-
ogist without a referral from their primary care
physician. Melanoma patients typically have contact
with their physicians in the year before diagnosis,
suggesting that many lesions may be diagnosed
earlier with the assistance of primary care providers
(PCPs).46 In fact, middle-aged and older men make
at least 3 to 4 visits per year to a physician or medical
care facility.85 A single survey of patients in waiting
rooms found that 82% reported that it would be
appropriate for their PCP to conduct regular full-
body skin examinations, and 87% stated that they
would like their PCP to perform a full-body skin
exam regularly.86 Using a computer simulation
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model to simulate the effects of a hypothetical
melanoma screening program, Girgis87 suggested
that an every 5-year screening by family physicians
for men over the age of 50 would be cost-effective.
Much remains unknown about melanoma discov-
ery patterns and the differences between dermatol-
ogist and PCP biopsy and referral practices. Chen
et al88 performed a systematic review of 32 studies of
melanoma discovery patterns conducted before
2001 and found numerous information gaps, includ-
ing lack of consistent sensitivity and specificity data,
inadequate sample sizes, and data derived primarily
from residents rather than attending physicians.
Populations at high risk
Before launching an effective educational or early
detection program, it is necessary to identify patients
at moderate-to-high risk for developing melanoma.
Selective education and screening could be consid-
ered for individuals with the following high-risk
characteristics: middle-aged and older men, family
members of melanoma patients, personal history of
melanoma, nonmelanoma skin cancer patients,
transplant patients, low socioeconomic status (SES),
manymoles/atypical moles, fair skin, and blue/green
eyes, blonde/red hair.
Middle-aged and older men. It is well docu-
mented that men, particularly those aged 50 years or
older, have higher incidence and mortality rates for
melanoma. Of particular relevance to mortality rates,
during the past decade, the US incidence of thick
tumors ([4 mm) increased significantly only in men
aged 60 years and older.89 For this demographic, the
IOM report noted that evidence does support ben-
efits of early melanoma detection and treatment as
part of usual medical care and that clinicians and
patients should continue to be alert to the common
signs of skin cancer, with a particular emphasis on
older white males and on melanoma.46 A crucial step
in reducing melanoma mortality is first discovering,
then improving the sources that influence awareness
of early detection among this high-risk group.
Special efforts to reach men aged 50 years and up
led to increased screening as part of the Queensland
community-based trial. Men at the age of 50 or older
comprised 21% of all participants but accounted for
49% of all melanoma diagnoses.90 Likewise, persons
of varying educational levels increased screening
rates, likely resulting from well-designed promo-
tional materials.91
Family members of melanoma patients. A
randomized trial testing an intervention that provided
personalized telephone counseling and individually
tailored materials for siblings of recently-diagnosed
melanoma patients resulted in greater performance
of SSE (OR, 1.81; 95% CI, 1.04-3.71) at 12 months
for intervention siblings compared with controls
(receiving standard dermatologist education). The
number of participants in both groups that received
a skin cancer examination more than doubled, with
no differences between intervention and control
subjects.92 Earlier surveys on beliefs and practices
regarding skin cancer prevention and detection
among 404 siblings of recently diagnosed patients
with melanoma found that only 27% had received
a skin cancer examination by a dermatologist dur-
ing the past year; 47% had never received a der-
matologic examination. Multivariate analysis found
modifiable positive predictors for SSE and derma-
tologist examinations, including having a clinician
with whom to talk about melanoma and believ-
ing in the importance of regular skin examinations
by a physician.93 Manne et al94 found similar skin
cancer risk reduction practices of 229 first-degree
relatives (FDRs) of recently diagnosed melanoma
patients. Forty-five percent of FDRs had received
a physician recommendation to perform SSE but
only 24% were ever instructed on how to perform
the exam.
Personal history of melanoma. It is well
documented that personal history of melanoma is
one of the strongest risk factors for melanoma. Risk of
multiple primary melanoma was recently examined
among 4484 patients with primarymelanoma (follow-
up of 7 years). Nearly 9% had a second primary
melanoma diagnosis; 21% of these patients had a
family history of melanoma compared with 12% of
patients with a single primary melanoma. DN was
twice as common (38% v. 18%) in multiple primary
melanoma patients.95 In a study ofmelanoma patients
at the John Wayne Cancer Institute who received
routine education on the performance of the SSE and
clinical warning signs, tumor thickness decreased
from a mean of 1.32 for the initial melanoma to 0.63
mm for the second primary melanoma.96
Non-melanoma skin cancer patients and ac-
tinic keratoses. Numerous studies have found that
individuals who have a history of either basal cell
carcinoma or squamous cell carcinoma are at signif-
icantly increased risk of developing a subsequent
primary melanoma as compared to the general pop-
ulation. Although the studies vary with regard to the
level of risk (ranges from 2.5 to 10.0), all report that
NMSC is a significant risk factor for melanoma.97-106
In a retrospective observational study from the 1992-
1998 Medicare Current Beneficiary Study, the OR of
developing NMSC or melanoma was increased more
than sixfold in patients with actinic keratoses.107
Transplant patients. Kasiske et al108 examined
rates of malignancies among first-time recipients of
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deceased or living donor kidney transplantations in
1995-2001 (n = 35,765) using Medicare billing claims.
Compared with patients on the waiting list, several
tumors were more common after transplantation
including: NMSCs (2.6-fold), melanoma (2.2-fold),
Kaposi’s sarcoma (9.0-fold), non-Hodgkin’s lym-
phoma (3.3-fold), cancer of the mouth (2.2-fold),
and cancer of the kidney (39% higher).108 An analysis
(1988-1998) of the US Renal Data System (89,786
patients) found 246 melanomas in kidney transplant
patients, or a 3.6 fold difference when compared
with the general population.109
Persons of low socioeconomic status/poor
health access. While it is well known that persons
with higher education or income are more likely to
be diagnosed with melanoma, less is known about
the disproportionate burden of mortality for low SES
individuals or for minority populations. Latest exam-
ination of the US SEER registry found that overall
five-year survival was demonstrably less for minor-
ities (72%-81%) than for whites (89.6%).110
Reyes-Ortiz111 summarized the studies related to
the effect of SES on melanoma stage at diagnosis. Of
the 12 studies analyzed (8 population-based), all
found increased rates of advanced stage melanoma
or decreased survival in lower SES individuals.
Various indices of social class were used including
occupation, education, social class areas, physician
supply, and poverty rates. SEER data from records
(1988-99) of more than 23,000 melanoma patients
were reviewed to assess 5-year melanoma survival.
Older patients living in lower SES areas had worse
melanoma survival than those from high SES
areas.112
Thicker melanomas ([1.5 mm) were also three
times more common in patients with low levels of
education or unemployment in Italy.113 In a study of
incident cases of melanoma, colorectal cancer, breast
cancer, and prostate cancers diagnosed in Florida,
patients who were uninsured were most likely to be
diagnosed with a later stage cancer. In fact, lack of
insurance wasmore commonly associated with later-
stage melanoma than for other cancers.114 A merge
of Florida state tumor registry data with state physi-
cian manpower data revealed that each additional
dermatologist per 10,000 residents was associated
with a 39% increased likelihood of earlier diagnosis.
Roetzheim et al115 suggested that AAD screenings
branch out to areas with the shortest supply of
dermatologists. In a US National Health Interview
Study, having health insurance and a usual source of
health care were important predictors for skin cancer
screening with few differences between men and
women.116 A UK study found reluctance to seek
advice for a suspect lesion was most pronounced
among persons from socially deprived districts,
suggesting that there could be significant attitudinal
barriers to screening among certain groups.117
A Behavioral Risk Factor Surveillance Study in
Massachusetts conducted in 2002 found the lack of
education to be the strongest predictor for unaware-
ness of melanoma as being a cancer of the skin. Only
59% of persons with less than a high school degree
correctly defined melanoman compared to more
than 90% for people with a college degree.118
Many moles/atypical moles. Oliveria et al
conducted a randomized trial of patients with five
or more dysplastic nevi; half of patients received a
teaching intervention (physician and nurse educa-
tion module) with a photo book (personal whole-
body photographs compiled in the form of a booklet,
with nurse instruction on how to use the photo-
graphs), and the remainder received only the teach-
ing intervention. Four months later, 61% patients in
the photo book intervention reported skin examina-
tion three or more times (P = .039 for paired
comparison) compared with 37% in the group re-
ceiving the teaching intervention alone.119
NEW TECHNOLOGIES: DERMOSCOPY
AND PHOTOGRAPHY
We highlight the dermoscopy studies from meta-
analyses, randomized trials, links with other out-
come data (eg, cancer registries), and comparisons
with naked-eye examinations.
Annual total cutaneous examination, total cutane-
ous photography, and dermoscopy were employed
for patients with classic atypical mole syndrome
(CAMS) and a heterogeneous group of patients
at high risk (ie, those with high-risk non-CAMS
[HRNCAMS]). A total of 258 patients (160 CAMS and
98 HRNCAMS) were studied. In the CAMS cohort, 28
new MMs developed in 19 patients resulting in a
cumulative 10-year risk of 14% (95% CI; 7-20). In the
HRNCAMS cohort, 10 new MMs developed in 9
patients, and the cumulative 10-year risk was 10%
(95% confidence interval: 2-17). The MMs diagnosed
in both cohorts were either in situ or \1 mm in
Breslow thickness.120
Carli et al121 has conducted the only randomized
trial to test differences in the management of equiv-
ocal lesions between the naked-eye examination,
naked-eye examination plus dermoscopy (with
mandatory excisions), and the possibility of digital
follow-up according to the clinician’s decision.
Patients in the combined arm had significantly fewer
lesions referred for surgery. However, the authors
expressed concern that the digital follow-up of
equivocal lesions was associated with a small occur-
rence of initial melanomas left unexcised.
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Meta-analysis of all studies performed before
2001 found that dermoscopy, when performed by
trained examiners, had greater discriminating power
for melanoma than clinical examination alone.
Bafounta et al122 called for improved technology to
reduce the proportion of false-negative findings.
Kittler123 conducted a meta-analysis of 27 studies
that compared the accuracy of melanoma diagnosis
with and without dermoscopy. Dermoscopy yielded
an improvement of 49% compared to naked eye
exams; however, dermoscopy by untrained or less
experienced examiners showed no improvements
compared with the clinical examination.
Four algorithms (the Menzies method, the 7-point
checklist, the ABCD rule, and pattern analysis) were
tested for diagnostic accuracy by 61 ‘‘nonexpert’’
physicians in Australia (35 GPs). More than half of
the physicians diagnosed 5 or fewer melanomas
annually. Clinical and dermoscopic image assess-
ment of 40 melanocytic skin lesions revealed high
rates of diagnostic accuracy (73-81%) following self-
guided training with all four algorithms. However,
the Menzies method showed the highest diagnostic
accuracy and sensitivity, and was most widely well-
accepted by study participants.124
In a study of 100 pigmented lesions for which no
agreement was reached, Carli et al125 found that an
examination of lesions based on morphologic fea-
tures (including dermoscopy), without any contact
with the patient, was associated with the risk of
incorrect classification in as many as 60% of early
melanomas, and as many as 30% of lesions were left
unexcised. The authors asserted that for equivocal,
hard-to-diagnose lesions, physicians should be
aware of potential risks associated with teleconsul-
tation or with automated melanoma derived from
using only digital instruments.
Massone et al126 noted that the accuracy of
traditional clinical diagnosis of melanoma ranges
between 65% and 80%, and concluded that the
naked-eye examination with the ABCD system may
fail to detect the so-called ‘‘small melanoma’’ as well
as melanomas regular in shape or color. Recognition
and prompt removal of lesions that are clinically or
dermoscopically suspicious for melanoma should be
the main aim of dermoscopy, as well as avoiding
unnecessary excision of benign lesions. Important
moves toward standardizing the dermoscopic diag-
nosis have been made via the development of the
Consensus Net Meeting on Dermoscopy (CNMD).
Forty trained dermoscopists from many countries
evaluated 108 lesions via the Internet using a 2-step
process that discriminated between melanocytic and
nonmelanocytic lesions. The most specific dermo-
scopic criteria for early melanoma detection were
asymmetry, atypical pigment network, and bluee
white structures. These criteria achieved a sensitivity
approaching 97%.127
Feit et al128 also found that follow-up photogra-
phy added to the detection of evolving, thin mela-
noma. Among all new melanomas, change in
baseline photos resulted in detection of 74% mela-
nomas;19% were new lesions. Many of the changing
lesions did not correspond with the clinical criteria
for melanoma but were most evident with careful
review of baseline and follow-up photographs.
Lucas et al129 found that lesions categorized as both
nonuniform and changed (by dermoscopy) were
more than four times as likely to be melanoma
compared with other categories: uniform and
changed, nonuniform and unchanged and uniform
and unchanged. Of the 16 melanomas found in the
study, none developed from an obvious dysplastic
nevus, 5 evolved from lesions that appeared to be
small nevi, 4 evolved in an area where a small
pinpoint focus of pigment could be identified, and
7 evolved in skin with no previous identifiable
lesion.129
Oliveria et al130 reviewed the emerging technol-
ogies and examined the many factors needed for
more broad-scale implementation including physi-
cian training, low-cost equipment, and research into
patient, physician, and health care system uptake of
new technologies.
PROFESSIONAL AND PUBLIC EDUCATION
We describe the prevalence of screening by phy-
sicians, medical students, and nurses, and report on
most recent professional training programs.
Skin cancer screening rates
While skin screening by PCPs may be an effective
tool in reducing advanced stage melanoma, in prac-
tice, the rates of screening (whether reported by the
public or professionals) are low. In a random survey
of the US adult population in 1998, only 21% had
ever had a full head-to-toe skin examination.131
Reports from 784 primary care visits to 109 family
practitioners and 61 internists as part of the 1997
National Ambulatory Care Survey revealed that skin
examinations were reported at only 16% of visits,
much lower than reported rates for other cancer
screenings.132 In a survey of patients in dermatology
and primary care clinic waiting rooms at a Veterans
Affairs medical center, 32% reported undergoing
regular full body skin examinations by their PCP.82
This rate did not differ between respondents in the
primary care or in the dermatology clinic.
Physicians report higher rates of screening than
the public. Altman et al133 surveyed almost 1400
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PCPs throughout the United States regarding their
cancer screening practices. Approximately 37% of
physicians reported screening most of their patients
for skin cancer.133 A more recent survey of family
medicine physicians, internists, and GPs sought to
determine the national rates of melanoma screening.
Sixty percent of eligible physicians responded, and
of these, nearly 60% physicians routinely performed
full-body examinations with their high-risk patients.
In the regression analysis of factors influencing
physician examination of high-risk patients, lack of
time was the strongest barrier [odds ratio (OR) 0.3
(95% confidence interval (CI) 0.2 to 0.6)]. Physicians
using the most information sources [OR 2.5 (95% CI
1.3 to 4.8)] were the most likely to examine their
high-risk patients. Physicians whose patients re-
quested a skin examination were more likely to
examine their patients compared with physicians
whose patients did not request such an examination
(P\ .01).134
While screening by PCPs has the potential of
being an effective screening tool, physicians and
medical students have noted various barriers to
doing skin screenings. Physicians and medical stu-
dents have noted a lack of time, skill, and confidence
as barriers to skin examinations.135,136 In a survey of
nearly 500 PCPs, Kirsner et al135 noted that 50% felt
that their lack of confidence in screening for skin
cancer was an important obstacle.
Physician interventions
Forty-one family physicians in Tuscany received a
4-hour training session on the diagnosis, manage-
ment, and decision plans for dermatology referrals.
Training led to a marked increase in melanoma
diagnosis (using slides) with a concomitant improve-
ment in specificity (55-73%) for a dermatology
referral.137 Harris et al138 demonstrated increased
confidence in identifying suspicious lesions through
the use on an Internet Continuing Medical Education
program to 354 US physicians. Satisfaction among
physician users was nearly 90%. In a controlled study
of an Internet-based skin cancer triage intervention
for physicians, Gerbert et al139 found intervention
effects for physician skin cancer diagnosis and eval-
uation planning. Although the study was limited by
questions asked immediately after a lecture, a study
of Belgian GPs found improvements in the propor-
tion of pigmented lesions correctly identified.140 A
2-hour Basic Skin Cancer Triage (BSCT) curriculum
was designed to improve the skills, knowledge,
confidence, and attitudes of 28 PCPs in Rhode
Island. Significant changes from pretest to posttest
were made in provider ability to accurately diagnose
and triage lesions, provide reassurance about
lesions, and improve knowledge of skin cancer
control practices.141 Successful utilization of the
BSCT curriculum in broader settings awaits further
study. An educational video shown to randomly
selected family physicians did not result in significant
differences in the proportion of malignant lesions
biopsied.142
Medical school training
In a 2004 study of more than 650 fourth-year
students at seven US medical schools, Moore et al143
found that 43% had never performed a skin cancer
screening exam. However, students performing at
least one examination were nearly 3 times more
likely to report being moderately skilled in the skin
cancer exam. Brandling-Bennett et al144 conducted
focus groups with New England medical students to
discover optimal venues within the medical school
curriculum to insert skin cancer education. Lee
et al136 reported that third year medical students at
UCLA felt least competent in performing skin cancer
examinations compared to clinical breast, Pap smear,
and digital rectal exams.
Nurses
A 1997 survey of 457 Texas nurses found that 61%
believed that skin cancer detection was part of their
practice; more than 60%, however, noted that lack of
national guidelines and low priority of skin screen-
ing by doctors served as key barriers.145 Using the
consensus clinical diagnosis of the dermatologists as
the gold standard, the nurse practitioner’s sensitivity
for detecting significant skin cancer lesions ranged
from 50% to 100% and the detection specificity was
99% to 100%.146
Public and patient education
In the past 5 years, numerous organizations and
foundations have launched melanoma Web sites
replete with photographs of normal and abnormal
lesions and techniques to perform SSE.147-149 One
study found that the majority of Web sites failed to
include complete information on general informa-
tion, risk factors, diagnosis, treatment, prevention,
and prognosis. Medical information retrieved with
the search term melanoma was likely to lack com-
plete basic melanoma information and contained
inaccuracies in 14% of sites.150 Bichakjian et al150
noted that health care providers can help patients by
recommending comprehensive and accurate Web
sites, by working to create accurate and thorough
Web-based health information material, and by ed-
ucating patients and the public about the variability
in completeness and accuracy. Bhavnani151 investi-
gated the way that facts on melanoma were
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distributed across high-quality Web pages using
inter-rater experiments with skin cancer physicians.
In-person training of the public and teaching about
the ABCD criteria resulted in better assessments of
common moles and dysplastic nevi (DN). Branstrom
et al152 conducted a study of 120 Swedish residents
(30 each with pigmented lesions, DNs, melanoma,
and from a healthy population) and found reason-
ably good ability to identify malignant changes but
less ability to recognize common moles and DN.
Two randomized trials have tested different
methods of patient education. One found that
knowledge of melanoma improved with the use of
a videotape compared with a clinic visit; however,
physician encounters were more effective in reduc-
ing patient anxiety or distress.153 A second study
used different methods to engage patients in recog-
nition of early melanoma and found photographs to
be far superior to use of only the ABCD rule.154
CONCLUSIONS
With the recent, abrupt cessation of the popula-
tion-based, randomized screening trial in
Queensland, randomized studies of large cohorts
with many years of follow-up, as required to rigor-
ously demonstrate that early detection of melanoma
is desirable, may never be funded. Thus, there is the
possibility that we will never have the evidence
required to conclude that screening effectively re-
duces melanoma mortality.
Disturbingly low screening rates in the presence
of persistent and avoidable mortality prompt a call
for new and far-reaching approaches, including
ways to make screening more available to under-
served individuals, targeted education to the high-
risk public, and ‘‘early’’ professional education to
health professional students in all disciplines.155 In
Australia, where early detection (or screening) cam-
paigns were initiated earlier than in Europe, a shift
toward thinner lesions, more SSM melanomas, and
fewer NMs has been observed over time, and has
been accompanied by improvements in melanoma
survival. In most industrialized nations, much pro-
gress has been made in detecting earlier lesions,
reducing case-fatality, and improving survival.
Dramatic progress at the population level, as evident
in Australia, hopefully foreshadows subsequent ef-
forts in the United States and elsewhere.
We are left with a number of questions derived
from the summary review above: (1) Can new
technologies and advances in vigilant surveillance
of persons with key risk factors for melanoma be
extendedmore broadly to persons with less access to
expert dermatologic care? (2) Can we deepen our
understanding of the biologic, clinical, and
behavioral antecedents of NM that now comprises
a disproportionate burden of late-stage melanoma?
(3) Can the widespread proliferation of Internet
information for physicians and the public alike be
harnessed to identify early curablemelanoma among
ourmost at-risk Americans? (4) Can randomized trials
testing some or all of the strategies described earlier-
public education, physician screening, and skin self-
examination be conducted to gather most relevant
information for planning large-scale programs?
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